The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial
Open accessAbstract
Background: Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown. Hypothesis/Objectives: Administration of pimobendan (0.4–0.6 mg/kg/d in divided doses) to dogs with increased heart size secondary to preclinical MMVD, not receiving other cardiovascular medications, will delay the onset of signs of CHF, cardiac-related death, or euthanasia. Animals: 360 client-owned dogs with MMVD with left atrial-to-aortic ratio ≥1.6, normalized left ventricular internal diameter in diastole ≥1.7, and vertebral heart sum >10.5. Methods: Prospective, randomized, placebo-controlled, blinded, multicenter clinical trial. Primary outcome variable was time to a composite of the onset of CHF, cardiac-related death, or euthanasia. Results: Median time to primary endpoint was 1228 days (95% CI: 856–NA) in the pimobendan group and 766 days (95% CI: 667–875) in the placebo group (P = .0038). Hazard ratio for the pimobendan group was 0.64 (95% CI: 0.47–0.87) compared with the placebo group. The benefit persisted after adjustment for other variables. Adverse events were not different between treatment groups. Dogs in the pimobendan group lived longer (median survival time was 1059 days (95% CI: 952–NA) in the pimobendan group and 902 days (95% CI: 747–1061) in the placebo group) (P = .012). Conclusions and Clinical Importance: Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated. Prolongation of preclinical period by approximately 15 months represents substantial clinical benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147 · cited 1×
“Potential explanations of the increased likelihood of industry-sponsored research having positive findings include the following: Industrial sponsors might be more likely to support studies that are likely to succeed, industrial sponsors might design studies with an inappropriate comparator group, or there might be pu…”
BackgroundStatistics notes: How to randomise
Altman, D. G., & Bland, J. M. (1999) · BMJ · doi:10.1136/bmj.319.7211.703 · Cited by 506
Compliance with Results Reporting at ClinicalTrials.gov
Anderson, M. L., Chiswell, K., Peterson, E. D., Tasneem, A., Topping, J., & Califf, R. M. (2015) · New England Journal of Medicine · doi:10.1056/nejmsa1409364 · Cited by 380
When to stop a clinical trial.
Pocock, S. J. (1992) · BMJ · doi:10.1136/bmj.305.6847.235 · Cited by 255 · cited 1×
“The decision to stop a clinical trial is a difficult one and involves weighing up the validity of the conclusions that can be drawn from a foreshortened study against the risks to animals remaining in a treatment trial where 1 method of treatment appears clearly more efficacious than the other.(28) There are risks ass…”
Background
Cited by
Keene, B. W., Atkins, C. E., Bonagura, J. D., Fox, P. R., Häggström, J., Fuentes, V. L., Oyama, M. A., Rush, J. E., Stepien, R., & Uechi, M. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15488 · Cited by 831
Self-citationThe renin-angiotensin-aldosterone system and its suppression
Ames, M. K., Atkins, C. E., & Pitt, B. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15454 · Cited by 433
Axelsson, E., Ljungvall, I., Bhoumik, P., Conn, L. B., Muren, E., Ohlsson, Å., Olsen, L. H., Engdahl, K., Hagman, R., Hanson, J., et al. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009726 · Cited by 34
Self-citation
Metadata
- Authors
- Boswood, A., Häggström, J., Gordon, S. G., Wess, G., Stepien, R. L., Oyama, M. A., Keene, B. W., Bonagura, J., MacDonald, K. A., Patteson, M., Smith, S., Fox, P. R., Sanderson, K., Woolley, R., Szatmári, V., Menaut, P., Church, W. M., O'Sullivan, M. L., Jaudon, J.-P., Kresken, J.-G., Rush, J., Barrett, K. A., Rosenthal, S. L., Saunders, A. B., Ljungvall, I., Deinert, M., Bomassi, E., Estrada, A. H., Fernandez Del Palacio, M. J., Moise, N. S., Abbott, J. A., Fujii, Y., Spier, A., Luethy, M. W., Santilli, R. A., Uechi, M., Tidholm, A., & Watson, P.
- Venue
- Journal of Veterinary Internal Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-11-01
- Volume
- 30
- Issue
- 6
- Pages
- 1765-1779
- ISSN
- 0891-6640 (ISSN-L)
- 1939-1676
- OpenAlex
- W2525681105
- Cited by
- 325
- References
- 4
- FWCI
- 33.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.